Endocrine oncology (Bristol, England)最新文献_第8页

Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal? 垂体瘤与罹患其他恶性肿瘤的风险：是巧合还是因果关系？

Endocrine oncology (Bristol, England) Pub Date : 2022-12-22 eCollection Date: 2022-01-01 DOI: 10.1530/EO-21-0033

Sandra Pekic, Marko Stojanovic, Vera Popovic

{"title":"Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal?","authors":"Sandra Pekic, Marko Stojanovic, Vera Popovic","doi":"10.1530/EO-21-0033","DOIUrl":"10.1530/EO-21-0033","url":null,"abstract":"Pituitary adenomas are benign neoplasms of the pituitary. The most prevalent are prolactinomas and non-functioning pituitary adenomas, followed by growth hormone- and ACTH-secreting adenomas. Most pituitary adenomas seem to be sporadic and their persistent growth is very atypical. No molecular markers predict their behavior. The occurrence of pituitary adenomas and malignancies in the same patient can be either pure coincidence or caused by shared underlying genetic susceptibility involved in tumorigenesis. Detailed family history on cancers/tumors in the first, second and third generation of family members on each side of the family has been reported in a few studies. They found an association of pituitary tumors with positive family history for breast, lung and colorectal cancer. We have reported that in about 50% of patients with pituitary adenomas, an association with positive family history for cancer has been found independent of secretory phenotype (acromegaly, prolactinoma, Cushing's disease or non-functioning pituitary adenomas). We also found earlier onset of pituitary tumors (younger age at diagnosis of pituitary tumors) in patients with a strong family history of cancer. In our recent unpublished series of 1300 patients with pituitary adenomas, 6.8% of patients were diagnosed with malignancy. The latency period between the diagnosis of pituitary adenoma and cancer was variable, and in 33% of patients, it was longer than 5 years. Besides the inherited trophic mechanisms (shared underlying genetic variants), the potential influence of shared complex epigenetic influences (environmental and behavioral factors - obesity, smoking, alcohol intake and insulin resistance) is discussed. Further studies are needed to better understand if patients with pituitary adenomas are at increased risk for cancer.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"2 1","pages":"R1-R13"},"PeriodicalIF":0.0,"publicationDate":"2022-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma. 卡麦角林治疗催乳素瘤时引发的三尖瓣瓣膜病变。

Endocrine oncology (Bristol, England) Pub Date : 2022-12-14 eCollection Date: 2023-01-01 DOI: 10.1530/EO-22-0086

Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sousa

{"title":"Cabergoline-associated valvulopathy of the tricuspid valve in the treatment of prolactinoma.","authors":"Annabelle G Hayes, Masoumeh G Shirazi, Anand Thiyagarajah, David J Torpy, Sunita M C De Sousa","doi":"10.1530/EO-22-0086","DOIUrl":"10.1530/EO-22-0086","url":null,"abstract":"Cabergoline-associated valvulopathy (CAV) is defined by the echocardiographic triad of moderate or severe regurgitation, valvular thickening and restricted valvular motion. While it is a well-described complication of dopamine agonist therapy in Parkinson's disease, only three convincing cases of CAV have previously been described in the treatment of prolactinoma, with none involving the tricuspid valve. We describe a case of CAV affecting the tricuspid valve, ultimately resulting in the patient's death. The novel finding of CAV affecting the tricuspid valve suggests a possible link between confirmed cases of CAV and the echocardiographic surveillance studies of cabergoline-treated prolactinoma patients which have mostly demonstrated subclinical tricuspid valve changes. The risk of CAV, although small, prompts a mindful prescription of dopamine agonist therapy for prolactinomas and consideration of measures to minimise cabergoline exposure. The cumulative cabergoline doses and duration of therapy associated with CAV in published cases exceed what has been evaluated in case series and surveillance studies, underscoring the importance of case reports in understanding CAV.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"3 1","pages":"e220086"},"PeriodicalIF":0.0,"publicationDate":"2022-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/84/89/EO-22-0086.PMC10305698.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9869875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis suppression. 免疫疗法引起的下丘脑-垂体-肾上腺轴抑制的潜在诊断误区。

Endocrine oncology (Bristol, England) Pub Date : 2022-08-09 eCollection Date: 2022-01-01 DOI: 10.1530/EO-22-0069

Darran Mc Donald, Rachel Katherine Crowley

引用次数: 0

Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes. 嗜铬细胞瘤和副神经节瘤：种系遗传学和遗传综合征。

Endocrine oncology (Bristol, England) Pub Date : 2022-06-28 eCollection Date: 2022-01-01 DOI: 10.1530/EO-22-0044

Christie G Turin, Molly M Crenshaw, Lauren Fishbein

引用次数: 0

Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management? 多巴胺激动剂治疗泌乳素瘤：我们是否需要重新思考手术在泌乳素瘤治疗中的地位？

Endocrine oncology (Bristol, England) Pub Date : 2022-04-21 eCollection Date: 2022-01-01 DOI: 10.1530/EO-21-0038

Sunita M C De Sousa

{"title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?","authors":"Sunita M C De Sousa","doi":"10.1530/EO-21-0038","DOIUrl":"10.1530/EO-21-0038","url":null,"abstract":"The current treatment paradigm for prolactinomas involves dopamine agonist (DA) therapy as the first-line treatment, with surgical resection reserved for cases where there is DA failure due to resistance or intolerance. This review highlights how DA therapy can be optimised to overcome its increasingly recognised pitfalls, whilst also addressing the potential for expanding the use of surgery in the management of prolactinomas. The first part of the review discusses the limitations of DA therapy, namely: DA resistance; common DA side effects; and the rare but serious DA-induced risks of cardiac valvulopathy, impulse control disorders, psychosis, CSF rhinorrhoea and tumour fibrosis. The second part of the review explores the role of surgery in prolactinoma management with reference to its current second-line position and recent calls for surgery to be considered as an alternative first-line treatment alongside DA therapy. Randomised trials comparing medical vs surgical therapy for prolactinomas are currently underway. Pending these results, a low surgical threshold approach is herein proposed, whereby DA therapy remains the default treatment for prolactinomas unless there are specific triggers to consider surgery, including concern regarding DA side effects or risks in vulnerable patients, persistent and bothersome DA side effects, emergence of any serious risks of DA therapy, expected need for long-term DA therapy, as well as the traditional indications for surgery. This approach should optimise the use of DA therapy for those who will most benefit from it, whilst instituting surgery early in others in order to minimise the cumulative burden of prolonged DA therapy.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"2 1","pages":"R31-R50"},"PeriodicalIF":0.0,"publicationDate":"2022-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/fb/EO-21-0038.PMC10259306.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pituitary carcinoma: reclassification and implications in the NET schema. 垂体癌：NET 方案中的重新分类和影响。

Endocrine oncology (Bristol, England) Pub Date : 2022-03-30 eCollection Date: 2022-01-01 DOI: 10.1530/EO-22-0041

Sylvia L Asa, Shereen Ezzat

{"title":"Pituitary carcinoma: reclassification and implications in the NET schema.","authors":"Sylvia L Asa, Shereen Ezzat","doi":"10.1530/EO-22-0041","DOIUrl":"10.1530/EO-22-0041","url":null,"abstract":"The entity known as pituitary carcinoma has been traditionally defined as a tumor of adenohypophysial cells that metastasizes systemically or craniospinally independent of the histological appearance of the lesion. Reported cases of pituitary carcinoma have clinically and histologically resembled their non-metastatic counterparts that were classified as adenomas; the majority of cases were initially diagnosed as adenomas, and with tumor progression and spread, the diagnosis was changed to carcinoma. This classification has been challenged since the definition of malignancy in most organs is not based only on metastatic spread. The extent of local invasion resulting in an inability to completely resect an adenohypophysial tumor can have serious consequences that can cause harm and are therefore not benign. To address this dilemma, it was proposed that pituitary tumors be classified as neuroendocrine tumors. This change in nomenclature is totally appropriate since these tumors are composed of classical neuroendocrine cells; as with other neuroendocrine tumors, they have variable behavior that can be indolent but can involve metastasis. With the new nomenclature, there is no requirement for a distinction between adenomas and carcinomas. Moreover, the WHO/IARC has provided an overarching classification for neuroendocrine neoplasms at all body sites; in this new classification, the term 'neuroendocrine carcinoma' is reserved for poorly differentiated high-grade malignancies that are clinically, morphologically and genetically distinct from well-differentiated neuroendocrine tumors. It remains to be determined if there are true pituitary neuroendocrine carcinomas.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"2 1","pages":"R14-R23"},"PeriodicalIF":0.0,"publicationDate":"2022-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fd/c3/EO-22-0041.PMC10259303.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options. 肾上腺皮质癌的辅助治疗:预后因素和治疗选择。

Endocrine oncology (Bristol, England) Pub Date : 2022-01-01 DOI: 10.1530/EO-22-0050

Ruaa Al-Ward, Celeste Zsembery, Mouhammed Amir Habra

{"title":"Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options.","authors":"Ruaa Al-Ward, Celeste Zsembery, Mouhammed Amir Habra","doi":"10.1530/EO-22-0050","DOIUrl":"https://doi.org/10.1530/EO-22-0050","url":null,"abstract":"Adrenocortical carcinoma (ACC) is a rare cancer with high recurrence rates and heterogeneous clinical behavior. The role of adjuvant therapy remains unclear because of the challenges in collecting high-quality data for a rare cancer. The current treatment recommendations and guidelines for adjuvant therapy are mostly derived retrospectively from national databases and the treatment outcomes of patients seen in referral centers. To better select patients for adjuvant therapy, multiple factors need to be considered including staging, markers of cellular proliferation (such as Ki67%), resection margins, hormonal function, and possibly genetic alterations of the tumor as well as patient-related factors such as age and performance status. Adjuvant mitotane remains the most commonly used adjuvant therapy in ACC based on clinical practice guidelines, though emerging data from ADIUVO trial (mitotane vs observation in low-risk ACC) suggest that mitotane use in low-risk patients may not be needed. An ongoing clinical trial (ADIUVO-2) is evaluating the role of mitotane vs mitotane combined with chemotherapy in high-risk ACC. The use of adjuvant therapy has been controversial but can be justified in select patients with positive resection margins or after the resection of localized recurrence. A prospective study is needed to study the role of adjuvant radiation in ACC as radiation is expected to help only with local control without impact on distant microscopic metastases. There are no recommendations or published data about using adjuvant immunotherapy in ACC, but this may be a future study after establishing the efficacy and safety profile of immunotherapy in metastatic ACC.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"2 1","pages":"R90-R101"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b5/cf/EO-22-0050.PMC10259337.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9805304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transient remission of hyperparathyroidism after fine-needle aspiration biopsy. 细针穿刺活检后甲状旁腺功能亢进的短暂缓解。

Endocrine oncology (Bristol, England) Pub Date : 2022-01-01 DOI: 10.1530/EO-22-0060

Ana Rita Elvas, Andreia Martins Fernandes, Sara Reis, Joana Couto, Raquel G Martins, Jacinta Santos, Teresa Martins, Bernardo Marques, Joana Guimarães, Fernando J C Rodrigues

{"title":"Transient remission of hyperparathyroidism after fine-needle aspiration biopsy.","authors":"Ana Rita Elvas, Andreia Martins Fernandes, Sara Reis, Joana Couto, Raquel G Martins, Jacinta Santos, Teresa Martins, Bernardo Marques, Joana Guimarães, Fernando J C Rodrigues","doi":"10.1530/EO-22-0060","DOIUrl":"https://doi.org/10.1530/EO-22-0060","url":null,"abstract":"Primary hyperparathyroidism (PHPT) is the unregulated overproduction of parathyroid hormone (PTH), resulting in abnormal calcium homeostasis. PHPT is most commonly caused by a single adenoma of the parathyroid gland, which can have an intrathyroid location in rare cases. The measurement of intact PTH in the washout fluid obtained by ultrasound (US)-guided fineneedle aspiration (FNA) can be useful in clarifying the aetiology of these lesions. This study presented a 48-year-old man with a background history of symptomatic renal stone disease who was diagnosed with PHPT and referred to our Endocrinology department. A neck US revealed a thyroid nodule with a size of 21 mm in the right lobe. The patient underwent US-guided FNA of the lesion. The measurement of PTH in the washout fluid was significantly elevated. Following the procedure, he reported neck pain and noticed distal paraesthesias in the upper limbs. Blood test results showed significant hypocalcaemia and supplementation with calcium and calcitriol was started. The patient was closely monitored. Recurrence of hypercalcaemia was later observed, and the patient was submitted to surgery. We present a case of FNAinduced transitory remission of PHPT in a patient with an intrathyroid parathyroid adenoma. We conjecture that intra-nodular haemorrhage might have occurred, which temporarily affected the viability of the autonomous parathyroid tissue. A few similar cases of spontaneous or induced remission of PHPT after FNA have been previously described in the literature. This remission can be transitory or permanent, depending on the degree of cellular damage thus follow-up of these patients is recommended.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"2 1","pages":"K10-K14"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259349/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular mechanisms involved in somatostatin receptor regulation in corticotroph tumors: the role of cytoskeleton and USP8 mutations. 促皮质性肿瘤中生长抑素受体调控的分子机制:细胞骨架和USP8突变的作用。

Endocrine oncology (Bristol, England) Pub Date : 2022-01-01 DOI: 10.1530/EO-22-0042

Erika Peverelli, Donatella Treppiedi, Giovanna Mantovani

引用次数: 0

Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer. 前列腺癌中雄激素受体、共调节因子和先锋因子的细胞特异性。

Endocrine oncology (Bristol, England) Pub Date : 2022-01-01 DOI: 10.1530/EO-22-0065

Damien A Leach, Rayzel C Fernandes, Charlotte L Bevan

{"title":"Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.","authors":"Damien A Leach, Rayzel C Fernandes, Charlotte L Bevan","doi":"10.1530/EO-22-0065","DOIUrl":"https://doi.org/10.1530/EO-22-0065","url":null,"abstract":"Androgen signalling, through the transcription factor androgen receptor (AR), is vital to all stages of prostate development and most prostate cancer progression. AR signalling controls differentiation, morphogenesis, and function of the prostate. It also drives proliferation and survival in prostate cancer cells as the tumour progresses; given this importance, it is the main therapeutic target for disseminated disease. AR is also essential in the surrounding stroma, for the embryonic development of the prostate and controlling epithelial glandular development. Stromal AR is also important in cancer initiation, regulating paracrine factors that excite cancer cell proliferation, but lower stromal AR expression correlates with shorter time to progression/worse outcomes. The profile of AR target genes is different between benign and cancerous epithelial cells, between castrate-resistant prostate cancer cells and treatment-naïve cancer cells, between metastatic and primary cancer cells, and between epithelial cells and fibroblasts. This is also true of AR DNA-binding profiles. Potentially regulating the cellular specificity of AR binding and action are pioneer factors and coregulators, which control and influence the ability of AR to bind to chromatin and regulate gene expression. The expression of these factors differs between benign and cancerous cells, as well as throughout disease progression. The expression profile is also different between fibroblast and mesenchymal cell types. The functional importance of coregulators and pioneer factors in androgen signalling makes them attractive therapeutic targets, but given the contextual expression of these factors, it is essential to understand their roles in different cancerous and cell-lineage states.","PeriodicalId":72907,"journal":{"name":"Endocrine oncology (Bristol, England)","volume":"2 1","pages":"R112-R131"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10191705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3